For people with obesity plus metabolic dysfunction, GLP-1s look like one of the most powerful risk-reduction tools we have
The injectable route is what was moved to Category 2
For example, microbiome genome-wide association studies (mGWAS) have identified that variants of different genes (for example, VDR , LCT , NOD2 , FUT2 , and APOA5 ) that are associated with distinct gut microbiome compositions
For most private patients, this is the more practical route - particularly where GP referrals for weight management remain limited
It mimics a natural hormone in the body called GLP-1 (glucagon-like peptide-1), which helps regulate hunger and blood sugar
There is early research on experimental GLP-1 patches for various conditionsusing advanced microneedle delivery systems, but these remain in preclinical stages